Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Neurology

Treatment Options and Standards of Care

At a Glance

Treatment for Familial Cerebral Cavernous Malformation (FCCM) focuses on managing symptoms rather than removing all lesions. Doctors typically use watchful waiting for stable areas and reserve surgery for specific "culprit" lesions causing recurrent bleeding or uncontrollable seizures.

Deciding how to treat Familial Cerebral Cavernous Malformation (FCCM) is a delicate balancing act. Unlike sporadic cases where there is often just one lesion, the multi-focal nature of FCCM means that “curing” the condition by removing every lesion is not possible [1][2]. Instead, the standard of care focuses on managing symptoms, preventing complications, and targeting only the specific lesions that cause problems [3][4].

The Decision Tree: Watchful Waiting vs. Surgery

For most people with FCCM, the primary strategy is active surveillance, also known as “watchful waiting” [1]. This involves regular MRI scans (usually with SWI sequences) to monitor for new lesions or changes in existing ones [5][6].

  • Watchful Waiting is appropriate when: Lesions are not causing symptoms, are located in deep or “eloquent” (vital) areas of the brain, or have remained stable over time [1][7].
  • Surgical Resection is considered when: A specific lesion causes recurrent hemorrhages (bleeding), progressive neurological problems, or seizures that cannot be controlled with medication [1][3][8].

In FCCM, surgeons do not remove all lesions. They identify the “culprit” lesion—the one responsible for your symptoms—and focus only on that one to minimize surgical risk [3][9].

Managing Seizures and Epilepsy

Seizures are the most common reason for treatment in FCCM [10]. This management usually happens in two stages:

  1. Medication First: Most patients begin with anti-epileptic drugs (AEDs) to suppress seizure activity [11]. While these drugs do not treat the cavernoma itself, they help keep the brain’s electrical activity stable.
  2. Surgery for Seizure Control: If medication fails to stop the seizures (medically intractable epilepsy), surgery may be the best option [10]. To stop seizures effectively, the surgeon often removes both the cavernoma and the surrounding hemosiderin rim—the iron-stained brain tissue that acts as a trigger for seizures [12][13].

Medication Safety: Blood Thinners and Pain Relievers

Because FCCM involves leaky blood vessels, many patients wonder what over-the-counter medications are safe. While there is no universal ban, doctors generally recommend caution with medications that affect blood clotting, such as NSAIDs (like ibuprofen or naproxen) and aspirin [14][15]. For general headache relief, acetaminophen is often preferred. If you need prescription blood thinners for another condition (like a heart issue), your neurologist and cardiologist must collaborate closely to balance your risks [16][4].

Emerging Treatments: Propranolol and Clinical Trials

Currently, there are no FDA-approved medications specifically for FCCM, but research is moving quickly.

  • Propranolol: Originally a blood pressure medication, Propranolol is being studied for its potential to stabilize leaky blood vessels and reduce the frequency of bleeds and seizures in FCCM [17][18]. While not yet a “standard” treatment, some doctors may discuss its use based on emerging data [19][20].
  • Clinical Trials: Researchers are investigating several new pathways, including drugs that target the Rho-kinase (ROCK) pathway, which is involved in keeping vessel walls tight [13][14].

Because treatment for FCCM is highly specialized, it is often recommended to seek care at a CCM Center of Excellence. Learn more about this in Building Your Specialized Care Team.

Common questions in this guide

Can surgery cure familial cerebral cavernous malformation?
Because FCCM causes multiple lesions to form, it is not possible to cure the condition by removing all of them. Instead, surgeons focus only on removing specific "culprit" lesions that are actively causing recurrent bleeding or severe symptoms.
What does watchful waiting mean for FCCM?
Watchful waiting, or active surveillance, means your doctor will monitor your brain lesions over time using regular MRI scans. This is the primary strategy when your lesions are stable, located in sensitive brain areas, and not causing active symptoms.
What over-the-counter pain relievers are safe to take with FCCM?
Doctors generally advise caution with medications that affect blood clotting, such as ibuprofen, naproxen, or aspirin, because FCCM involves leaky blood vessels. For general headache relief, acetaminophen is typically recommended as a safer option.
How are seizures from cavernomas treated?
Seizures are initially treated with anti-epileptic drugs to help stabilize the brain's electrical activity. If these medications fail to control the seizures, surgery may be recommended to remove the problematic lesion and its surrounding iron-stained tissue.
Are there any new medications or clinical trials for FCCM?
While there are currently no FDA-approved medications specifically for FCCM, researchers are studying drugs like Propranolol to see if they can stabilize leaky blood vessels. Clinical trials are also exploring new targeted therapies.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which of my multiple lesions is considered the 'culprit' causing my current symptoms?
  2. 2.Is the goal of our plan to manage symptoms (watchful waiting) or to remove the lesion (surgery)?
  3. 3.How do we determine if my seizures are 'medically intractable' and if surgery should be considered?
  4. 4.What is your guidance regarding over-the-counter pain relievers for my headaches?
  5. 5.Are there any active clinical trials for FCCM that I might be eligible for?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (20)
  1. 1

    Cerebral Cavernous Malformation: What a Practicing Clinician Should Know.

    Flemming KD, Lanzino G

    Mayo Clinic proceedings 2020; (95(9)):2005-2020 doi:10.1016/j.mayocp.2019.11.005.

    PMID: 32605781
  2. 2

    Multiple cerebral cavernous malformations: Clinical course of confirmed, assumed and non-familial disease.

    Santos AN, Rauschenbach L, Saban D, et al.

    European journal of neurology 2022; (29(5)):1427-1434 doi:10.1111/ene.15253.

    PMID: 35060255
  3. 3

    Surgical resection of cavernous angioma located within eloquent brain areas: International survey of the practical management among 19 specialized centers.

    Zanello M, Meyer B, Still M, et al.

    Seizure 2019; (69()):31-40 doi:10.1016/j.seizure.2019.03.022.

    PMID: 30959423
  4. 4

    Long-term antithrombotic therapy and risk of intracranial haemorrhage from cerebral cavernous malformations: a population-based cohort study, systematic review, and meta-analysis.

    Zuurbier SM, Hickman CR, Tolias CS, et al.

    The Lancet. Neurology 2019; (18(10)):935-941 doi:10.1016/S1474-4422(19)30231-5.

    PMID: 31401075
  5. 5

    Hemorrhage, Seizures, and Dynamic Changes of Familial versus Nonfamilial Cavernous Malformation: Systematic Review and Meta-analysis.

    Taslimi S, Ku JC, Modabbernia A, Macdonald RL

    World neurosurgery 2019; (126()):241-246 doi:10.1016/j.wneu.2019.02.115.

    PMID: 30851471
  6. 6

    Clinicoradiologic data of familial cerebral cavernous malformation with age-related disease burden.

    Kim S, Moon J, Jung KH, et al.

    Annals of clinical and translational neurology 2023; (10(3)):373-383 doi:10.1002/acn3.51728.

    PMID: 36629374
  7. 7

    Spinal involvement in pediatric familial cavernous malformation syndrome.

    Geraldo AF, Luis A, Alves CAPF, et al.

    Neuroradiology 2022; (64(8)):1671-1679 doi:10.1007/s00234-022-02958-1.

    PMID: 35451625
  8. 8

    Should we resect peri-lesional hemosiderin deposits when performing lesionectomy in patients with cavernoma-related epilepsy (CRE)?

    Dammann P, Schaller C, Sure U

    Neurosurgical review 2017; (40(1)):39-43 doi:10.1007/s10143-016-0797-5.

    PMID: 27822594
  9. 9

    Cavernoma of the Right Lateral Ventricle: A Rare Case Report.

    Katari UK, Prasanna GV, Gopidesi DT

    Asian journal of neurosurgery 2019; (14(4)):1222-1225 doi:10.4103/ajns.AJNS_161_19.

    PMID: 31903367
  10. 10

    Natural history of cerebral cavernous malformations.

    Ene C, Kaul A, Kim L

    Handbook of clinical neurology 2017; (143()):227-232 doi:10.1016/B978-0-444-63640-9.00021-7.

    PMID: 28552144
  11. 11

    Pharmacotherapy for cavernous malformations.

    Rudy RF, Du R

    Handbook of clinical neurology 2017; (143()):309-316 doi:10.1016/B978-0-444-63640-9.00031-X.

    PMID: 28552155
  12. 12

    Safety and effectiveness of stereotactic laser ablation for epileptogenic cerebral cavernous malformations.

    Willie JT, Malcolm JG, Stern MA, et al.

    Epilepsia 2019; (60(2)):220-232 doi:10.1111/epi.14634.

    PMID: 30653657
  13. 13

    Familial Cerebral Cavernous Malformations: Pathophysiology, Genetics, Biomarkers, and Treatment Perspectives.

    Fontes-Dantas FL, da Fontoura Galvão G, Cunha AM, et al.

    Journal of neurochemistry 2026; (170(1)):e70342 doi:10.1111/jnc.70342.

    PMID: 41486746
  14. 14

    Cerebral Cavernous Malformation: From Mechanism to Therapy.

    Snellings DA, Hong CC, Ren AA, et al.

    Circulation research 2021; (129(1)):195-215 doi:10.1161/CIRCRESAHA.121.318174.

    PMID: 34166073
  15. 15

    Emerging Pharmacologic Targets in Cerebral Cavernous Malformation and Potential Strategies to Alter the Natural History of a Difficult Disease: A Review.

    Chohan MO, Marchiò S, Morrison LA, et al.

    JAMA neurology 2019; (76(4)):492-500 doi:10.1001/jamaneurol.2018.3634.

    PMID: 30476961
  16. 16

    Magnetic Resonance Imaging of Multiple Cerebral and Spinal Cavernous Malformations of a Patient with Dementia and Tetraparesis.

    Antonescu F, Butnariu I, Cojocaru FM, et al.

    Diagnostics (Basel, Switzerland) 2022; (12(3)) doi:10.3390/diagnostics12030677.

    PMID: 35328230
  17. 17

    Safety and efficacy of propranolol for treatment of familial cerebral cavernous malformations (Treat_CCM): a randomised, open-label, blinded-endpoint, phase 2 pilot trial.

    Lanfranconi S, Scola E, Meessen JMTA, et al.

    The Lancet. Neurology 2023; (22(1)):35-44 doi:10.1016/S1474-4422(22)00409-4.

    PMID: 36403580
  18. 18

    Propranolol Reduces the Development of Lesions and Rescues Barrier Function in Cerebral Cavernous Malformations: A Preclinical Study.

    Oldenburg J, Malinverno M, Globisch MA, et al.

    Stroke 2021; (52(4)):1418-1427 doi:10.1161/STROKEAHA.120.029676.

    PMID: 33618555
  19. 19

    Propranolol or Beta-Blockers for Cerebral Cavernous Malformation: a Systematic Review and Meta-analysis of Literature in Both Preclinical and Clinical Studies.

    Ikramuddin S, Liu S, Ryan D, et al.

    Translational stroke research 2024; (15(6)):1088-1097 doi:10.1007/s12975-023-01199-5.

    PMID: 37857790
  20. 20

    Could propranolol be beneficial in adult cerebral cavernous malformations?

    Apra C, Dumot C, Bourdillon P, Pelissou-Guyotat I

    Neurosurgical review 2019; (42(2)):403-408 doi:10.1007/s10143-018-01074-0.

    PMID: 30610500

This page provides educational information on FCCM treatment options. Always consult your neurologist or neurosurgeon to determine the safest care plan for your specific lesions.

Get notified when new evidence is published on Familial cerebral cavernous malformation.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.